News

Trials of early-stage study on coronavirus vaccine show promise

The single-blind, randomised, controlled trial found that neutralising antibody responses were reported in 91% of 35 patients when utilising one test and 100% of 35 patients when using a different test

Shares of AstraZeneca, 0.93% were down 3.4% in trading on 20 July after a medical journal published a study that found the company’s Covid-19 vaccine candidate produced antibody and T-cell responses in participants in a Phase 1/2 clinical trial.

AstraZeneca is developing the experimental vaccine with the University of Oxford; the study was published in The Lancet.

WSJ Logo